Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO(BMY) · Entity 1662 | VP & Financial Controller | March 15, 2004 | March 17, 2004 |
| MusclePharm CorpMSLP · Entity 125097 | Director | June 01, 2021 | June 11, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRISTOL MYERS SQUIBB CO
Report date March 15, 2004 · Filed March 17, 2004
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Share UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,880.28 |
Reported balance
After 2004-03-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2004-03-15 · Grant · Acquired 2,880.28 · Balance 2,880.28 F1: Consists of deferred share units accrued under the 1997 Performance Incentive Plan. F2: Deferred share units are settled in shares of stock either in one lump sum payment or in installments upon the employee's termination. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of deferred share units accrued under the 1997 Performance Incentive Plan.
F2: Deferred share units are settled in shares of stock either in one lump sum payment or in installments upon the employee's termination.
MusclePharm Corp
Report date June 01, 2021 · Filed June 11, 2021
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2004 Filed Mar 17, 2004 15:37 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantDeferred Share Units · Derivative | 2,880.28 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000014272-04-000082 · kar238.xml · derivative · entry 1 KARR PAUL W · CIK 0001269198 · VP & Financial Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,880.28 Underlying: Common Stock, $0.10 par value · 2,880.28 shares Expires not disclosed F1 · shares: Consists of deferred share units accrued under the 1997 Performance Incentive Plan. F2 · derivative.exercise_date: Deferred share units are settled in shares of stock either in one lump sum payment or in installments upon the employee's termination. F2 · derivative.expiration_date: Deferred share units are settled in shares of stock either in one lump sum payment or in installments upon the employee's termination. Read SEC document |
| March 02, 2004 Filed Mar 4, 2004 22:25 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantOption (right to buy) · Derivative | 19,333 | $0.00 Strike: $28.11 | $0.00 |
DisclosureSEC source: 0000014272-04-000074 · kar225.xml · derivative · entry 2 KARR PAUL W · CIK 0001269198 · VP & Financial Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,333 Underlying: Common Stock, $0.10 par value · 19,333 shares Expires 2014-03-01 F2 · derivative.exercise_date: Exercisable as to 25% of the shares annually, on a cumulative basis, commencing one year after the date of grant. Read SEC document |
| March 02, 2004 Filed Mar 4, 2004 22:25 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantCommon Stock, $0.10 par value | 3,222 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-04-000074 · kar225.xml · nonDerivative · entry 1 KARR PAUL W · CIK 0001269198 · VP & Financial Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,222 F1 · shares: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date. Read SEC document |
| December 01, 2003 Filed Dec 2, 2003 22:02 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantOption (right to buy) · Derivative | 15,000 | $0.00 Strike: $26.63 | $0.00 |
DisclosureSEC source: 0000014272-03-000054 · kar176.xml · derivative · entry 2 KARR PAUL W · CIK 0001269198 · VP & Financial Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock, $0.10 par value · 15,000 shares Expires 2013-11-30 F2 · derivative.exercise_date: Exercisable as to 25% of the shares annually, on a cumulative basis, commencing one year after the date of grant. Read SEC document |
| December 01, 2003 Filed Dec 2, 2003 22:02 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantCommon Stock, $0.10 par value | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-03-000054 · kar176.xml · nonDerivative · entry 1 KARR PAUL W · CIK 0001269198 · VP & Financial Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · shares: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.